Medtronic Shares 3-Year Renal Denervation Blood Pressure Trial Data

Medtronic released three-year data from its SPYRAL HTN-ON MED and GSR-DEFINE trials at EuroPCR 2022, which detailed benefits of its Symplicity blood pressure procedure leveraging the Symplicity Spyral renal denervation (RDN) system to achieve target blood pressure level changes.
 
Medtronic’s Symplicity Spyral RDN uses a minimally invasive procedure to deliver radiofrequency energy to specific nerves near the kidneys that can become overactive and cause high blood pressure.
 
“The data presented today at EuroPCR provide meaningful insights into the benefits of RDN through a patient lens, looking at how much time they spend within a target BP range,” Jason Weidman, Medtronic’s senior VP and president of the Coronary & Renal Denervation business told the press. “This new data reinforces RDN’s effectiveness as a complementary solution for achieving better blood pressure control and reducing cardiovascular risk.”
 
Time in target range (TTR) is used to measure how well a parameter including blood pressure is controlled. The Society for Cardiovascular Angiography & Interventions and the National Kidney Foundation released a consensus statement recognizing TTR as an effective blood pressure measure, as well as endpoint in clinical trials and registries.
 
According to the SPYRAL HTN-ON MED trial data, TTR for patients treated with RDN (33.7% TTR) was nearly double of sham patients (18.8% TTR) through three years.
 
According to GSR-DEFINE trial data, RDN patients spent 34.9% time in TTR through three years. There was also a 16% decrease in major adverse cardiovascular events (MACE) associated with every 10% increase in TTR at six months.
 
“These three-year data showed us that RDN nearly doubles the time patients spend in their target blood pressure range, regardless of anti-hypertensive medications, reinforcing the long-term benefit of the procedure,” said Dr. David Kandzari, chief, Piedmont Heart Institute and Cardiovascular Services and SPYRAL HTN-ON MED lead principal investigator.